Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of apatinib in advanced lung cancer
ChiCTR1800018113Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in bronchial carcinoma, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Tumor diameter. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR1800018113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018113.